--- title: 'Medical Science Liaison – Neurodegeneration (United States) at Prilenia' canonical: 'https://feeny.ai/job/medical-science-liaison-neurodegeneration-united-states-prilenia-boston-wgsszzfrykr0' type: 'job' last_seen: '2026-09-14' --- # Medical Science Liaison – Neurodegeneration (United States) at Prilenia - **Company:** Prilenia - **Location:** Boston, MA - **Employment:** full-time - **Work type:** remote - **Posted:** 2026-04-24 - **Last confirmed live:** 2026-09-14 - **Apply:** https://jobs.lever.co/prilenia/111e73e7-5255-4537-aafd-092fd3bebe19 ## Job description ## About Prilenia Prilenia Therapeutics, a clinical-stage biotechnology company focused on the urgent mission of developing novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, is looking for a Medical Science Liaison (MSL) in the United States, to support programs in both Huntington’s Disease and ALS. We are a flexible, fast-moving team that is quickly advancing a potential therapy poised to have major impact on the lives of patients and their families. Our lead product candidate, pridopidine, holds Orphan Drug Designation in both Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS) in the U.S. and EU, as well as Fast Track designation from the FDA for the treatment of HD. Prilenia is conducting global Phase 3 clinical trials in both HD and ALS. ​ Pridopidine has the potential to be a pivotal treatment to address HD and ALS disease progression. Prilenia believes pridopidine’s novel mechanism of action as a Sigma-1 receptor agonist also gives it potential in numerous other neurodegenerative and neurodevelopmental conditions. To learn more about our story and company culture, visit us at https://Prilenia.com ## About the role We are seeking a highly motivated and experienced Medical Science Liaison (MSL) to join our dynamic Medical Affairs team in the United States. This is a field‑based role supporting the U.S. and Canada, and reporting to the Executive Medical Director. The MSL will serve as a scientific expert in HD and ALS while building collaborative partnerships with neurologists, thought leaders and multidisciplinary care teams to support Prilenia’s clinical trials and programs. Prilenia has offices in the U.S., Israel and The Netherlands. Prilenia is a highly virtual and flexible organization and encourages team members to work in the ways that make them most effective, with a focus on our common goals and drive to move things forward. Roles and Responsibilities: - KOL Engagement: - Identify, develop, and maintain relationships with KOLs, HCPs, and other stakeholders within the relevant therapeutic areas. - Engage in scientific exchange to provide and gather medical and scientific insights. - Represent the company at medical conferences, symposia, and meetings to establish and strengthen relationships with KOLs and other stakeholders. Scientific Communication: - Provide accurate, unbiased, and up-to-date scientific information to healthcare professionals. - Present clinical data and scientific information in various forums, including advisory boards, investigator meetings, and educational sessions. - Serve as a scientific resource for internal and external stakeholders. Medical Affairs Support: - Collaborate with cross-functional teams, including Clinical, Research, Regulatory, Patient Advocacy and Commercial, to provide scientific input and support. - Assist in the development of medical strategy and contribute to the execution of Medical Affairs plans. - Support Clinical Development initiatives, including site identification and patient recruitment for clinical trials. Market Insights: - Gather and communicate competitive intelligence and market insights to inform strategic decisions. - Provide feedback to internal teams on trends and emerging science in the field. - Leverage scientific knowledge and KOL relationships to identify opportunities for activities leading to scientific advancement. Compliance: - Ensure all activities and interactions comply with applicable local and international regulations, company policies, and ethical standards. Qualifications and Skills: - Education:  Advanced degree in life sciences (MD, PhD, PharmD, or equivalent). - Experience: Minimum of 5 years of reference supported high-performance in a similar MSL role, preferably in scale-up and rare disease environment. Demonstrated experience working with KOLs and understanding of the U.S. and Canadian healthcare systems. Experience in neurology and neurodegenerative therapeutic areas relevant to the company’s pipeline is highly desired. - Skills: Strong scientific acumen and ability to understand and effectively communicate complex scientific and clinical data. Excellent interpersonal and communication skills, both written and verbal. Ability to work independently and manage multiple priorities in a fast-paced environment. Proficient in Microsoft Office Suite and familiar with CRM tools. Location/Time Zones: This is a full-time, remote position in the US. Expected domestic/regional travel up to 70% with some international travel. Valid driver's license required. Flexible schedule with interactions across North America, Europe and Israel time zones. Prilenia operates across the United States, Canada, Europe and Israel, is incorporated in the Netherlands and backed by leading life sciences investors. We are a highly flexible organization that is mostly remote and encourages team members to work in the ways that make them most effective, with a focus on our common goals and getting the job done. Prilenia is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status. We are dedicated to fostering a diverse, inclusive, and welcoming workplace for all. ## About Prilenia ## Company Overview - **One-liner**: Prilenia is a clinical-stage biopharmaceutical company developing novel treatments for neurodegenerative and neurodevelopmental disorders, with a lead candidate targeting Huntington’s disease and ALS. - **Entity Type**: Private (clinical stage, backed by Series A and B funding) - **Headquarters**: Boston, Massachusetts, United States (with additional offices in Naarden, Netherlands and Herzliya, Israel) - **Founded**: 2018 - **Founders**: Dr. Michael Hayden, MBChB, PhD (CEO and founder of five prior biotech companies) ## Core Business - **Primary industry/industries**: Biotechnology / Therapeutics for neurodegenerative diseases - **Target customers**: B2B – healthcare providers, clinical trial sites, regulatory agencies, and ultimately patients with Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS) - **Mission or purpose statement**: “To develop and provide sustainable access to transformative medicines for people affected by devastating neurodegenerative diseases.” [prilenia.com](https://prilenia.com/about-us/) ## Products & Services - **[Pridopidine]**: A first-in-class, orally administered, potent and highly selective sigma-1 receptor (S1R) agonist designed to regulate neuroprotective mechanisms impaired in neurodegenerative diseases. It is currently being evaluated in a global Phase 3 trial (PROOF-HD) for Huntington’s disease and in the Phase 2/3 HEALEY platform trial for ALS. An additional confirmatory Phase 3 study (PRECISE-HD) began enrolling patients in August 2025. [prilenia.com](https://prilenia.com/about-us/) | [linkedin.com](https://linkedin.com/company/prilenia) ## Market Standing - **Valuation/Market Cap**: Not publicly disclosed (private company) - **Key Metric**: Total Funding – $115.5M across two rounds; Annual Revenue – $4.5M (estimated) - **Notable Investors/Partners**: - **Lead Investors**: Forbion Capital Partners, Morningside Venture Partners - **Commercial Partner**: Ferrer (collaboration and license agreement for commercialization and co-development of pridopidine in Europe and select international markets, announced April 2025) [prilenia.com](https://prilenia.com/about-us/) - **Growth Signals**: - Headcount grew 7% YoY (now 39 employees) [linkedin.com](https://linkedin.com/company/prilenia) - Active job postings increased 250% year-over-year, indicating scaling [linkedin.com](https://linkedin.com/company/prilenia) - First patient randomized in the PRECISE-HD confirmatory Phase 3 study (August 2025) [linkedin.com](https://linkedin.com/company/prilenia) ## Competitive Advantages - **First-in-class mechanism**: Pridopidine is a highly selective S1R agonist with a differentiated mode of action aimed at restoring cellular function in neurodegenerative diseases. - **Established safety profile**: The drug has been studied in multiple clinical trials, providing a strong safety dataset. - **Experienced leadership**: CEO Michael Hayden previously led Global R&D at Teva and oversaw 35 drug approvals. - **Global footprint**: Operations across the US, Canada, Europe, and Israel, with a remote-first culture that attracts top talent. ## Strategic Focus - **Near-term priority**: Complete enrollment and generate data from the Phase 3 PROOF-HD and PRECISE-HD trials in Huntington’s disease, and continue the HEALEY platform trial in ALS. - **Commercialization preparation**: Partner with Ferrer in Europe to prepare for potential launch, while retaining full rights in North America, Japan, and Asia Pacific. - **Pipeline expansion**: Evaluate pridopidine in additional indications and explore new assets for neurodegenerative and neurodevelopmental disorders. ## Why Work Here - **Mission-driven culture**: Employees are motivated by the urgent need to bring treatments to patients with devastating diseases. - **Remote/hybrid policy**: “Working mostly remotely across Israel, Europe, and North America” – a flexible, distributed team environment. [prilenia.com](https://prilenia.com/join-us/) - **Small, dynamic team**: With only 39 employees, individuals have high ownership and impact across functions. - **Global collaboration**: Opportunity to work across time zones and cultures in a company backed by top-tier life sciences investors. - **Growth trajectory**: Increasing headcount and active hiring for roles in clinical operations, quality assurance, and medical science liaisons. ## Sources 1. [prilenia.com - About Us](https://prilenia.com/about-us/) 2. [prilenia.com - Join Us](https://prilenia.com/join-us/) 3. [prilenia.com - Our People](https://prilenia.com/our-people/) 4. [linkedin.com - Prilenia Company Page](https://linkedin.com/company/prilenia) ## Other roles at Prilenia - [Director/Senior Director, Safety-PV Operations Lead (EU)](https://feeny.ai/job/director-senior-director-safety-pv-operations-lead-eu-prilenia-europe-c33nd34btw7p) — Europe - [Director / Senior Director, GCP Quality Assurance Lead (US/IL/EU)](https://feeny.ai/job/director-senior-director-gcp-quality-assurance-lead-us-il-eu-prilenia-boston-eakx8fwxqhvd) — Boston, MA